Menu
Back to User profile » Dr Ying Guo
Papers published by Dr Ying Guo:
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ
Breast Cancer: Targets and Therapy 2024, 16:223-231
Published Date: 12 April 2024
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients
Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L
OncoTargets and Therapy 2014, 7:1301-1310
Published Date: 16 July 2014
Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment
Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L
OncoTargets and Therapy 2013, 6:811-818
Published Date: 3 July 2013
The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution
Zhang J, Huang Y, Li X, Guo Y, Zhao Y, Xue C, Hu Z, Zhang L, Zhao H
OncoTargets and Therapy 2012, 5:349-355
Published Date: 15 November 2012